Brief: Aroa Biosurgery Says Preliminary Unaudited FY23 Normalised EBITDA Positive
27/04/2023 02:30
April 27 (Reuters) - Aroa Biosurgery ARX.AX :
* PRELIMINARY UNAUDITED FY23 FULL YEAR NORMALISED EBITDA
POSITIVE
* PRELIM UNAUDITED FY23 TOTAL REVENUE ABOUT NZ$63.4 MILLION,
GROWTH OF 60%
Source text for Eikon: ID:nASX29W3nZ
Further company coverage: ARX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aroa Biosurgery
See all newsAustralia-listed Aroa Biosurgery climbs as annual earnings beat guidance
Brief: Aroa Biosurgery Posts Adjusted EBITDA Of NZ$12.6 Million
Aroa Biosurgery climbs as prelim annual results beat outlook
Brief: Aroa Biosurgery Posts FY26 Prelim Total Revenue Of NZ$104 Million
Brief: Aroa Biosurgery Says Expects FY26 Revenue At Upper End Of NZ$92-100 Million